Sulfateq
Netherlands - GroningenBiotechnology
Focus: Small molecule for acute kidney injury, diabetes, copd, pah
Sulfateq is a life sciences company focused on Small molecule for acute kidney injury, diabetes, copd, pah.
Profile data last refreshed Yesterday
Open Jobs
0
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Single ascending doses SUL-238
Healthy SubjectsClinical Trials (1)
NCT06277492A First-In-Human Study of Single and Multiple Ascending Doses of Oral SUL-238 in Healthy Subjects
Phase 1Help build intelligence for Sulfateq
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.